What Is Fisetin Studied For? Research Areas, Per the Literature

What this page answers

The question "what is fisetin used for" is answered here only as what fisetin has been studied for in the published literature. Fisetin is a flavonoid that occurs in plants and foods, and the sources cited on this page are cell culture experiments, animal experiments, and reviews that summarise preclinical work. Fisetin is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

Every research area below names the study type and the model or population in the same passage as its PubMed citation. Where a popular question has little or no supporting evidence in the sources cited here, that gap is stated plainly rather than filled in.

Evidence map at a glance

Senescence and aging biology

The most frequently discussed research area for fisetin is cellular senescence. A 2024 review in Mechanisms of Ageing and Development examined fisetin as a senotherapeutic agent and set out the evidence and perspectives for age-related diseases, framing fisetin as a candidate under investigation rather than an established intervention (PMID 39384074). Reviews of this kind summarise other laboratories' experiments and do not themselves generate new outcome data.

At the bench level, a 2025 study in International Journal of Molecular Sciences tested liposome-encapsulated fisetin against cellular senescence in laboratory models and reported evidence of a senomorphic effect, meaning that the researchers described modulation of the senescent phenotype in the systems studied rather than clinical benefit in people (PMID 40806616).

Why a dystrophic muscle study is often mentioned in this context

A 2022 animal study in Aging reported that senolytic elimination of senescent macrophages restored muscle stem cell function in severely dystrophic mouse muscle (PMID 36084954). That title describes senolytic elimination as a strategy and the model as severely dystrophic muscle in mice; it is cited here as context for why senescent cell clearance is studied in muscle biology, and it should not be read as a fisetin-specific outcome claim. Broader senotherapeutic framing for fisetin comes from the 2024 review rather than from that mouse experiment (PMID 39384074).

Fisetin among other geroscience candidates

Senescence and aging research evaluates several small molecules in parallel. A 2019 review in Gerontology surveyed metformin and aging, illustrating how a widely studied pharmaceutical has been examined for aging-related endpoints in its own literature (PMID 31522175). That review concerns metformin, not fisetin, and is included only to show that geroscience candidates are assessed separately, each on their own evidence base.

Neurological research

Neuroprotection is the second large cluster. A 2023 systematic review in Molecular Neurobiology collected studies on the neuroprotective role of fisetin across different neurological diseases, drawing on the published experimental literature in those disease models (PMID 37453993). A systematic review of preclinical work describes what laboratory and animal studies reported; it does not substitute for controlled trials in patients.

At the molecular level, a 2021 study in Molecules reported that the small molecule fisetin modulated alpha-synuclein aggregation in the assays used, a protein-level question relevant to synucleinopathy research (PMID 34199487). Aggregation chemistry in a test system is several steps removed from clinical neurology endpoints.

Cancer cell biology

Fisetin appears repeatedly in oncology laboratory research, where the study designs are cell-based or animal-based. A 2021 study in Aging reported that fisetin inhibited proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signalling in the models tested (PMID 34821587). A 2020 study in Drug Design, Development and Therapy reported that fisetin modulated human oral squamous cell carcinoma proliferation by blocking PAK4 signalling pathways in those cells (PMID 32158195).

A 2019 review in Biomolecules described fisetin and quercetin as flavonoids with chemopreventive potential, summarising the laboratory rationale for continued investigation (PMID 31064104). The word potential in that review title reflects the stage of the evidence: signalling-pathway findings in laboratory systems, not demonstrated cancer outcomes in people.

Cardiac and kidney models

A 2020 study in Scientific Reports reported that fisetin protected against cardiac cell death through reduction of reactive oxygen species production and caspase activity in the cardiac cell model studied (PMID 32076073). The readouts there were cell death pathways, not cardiovascular events.

In kidney research, a 2024 study in Acta Pharmacologica Sinica reported that fisetin ameliorated fibrotic kidney disease in mice by inhibiting ACSL4-mediated tubular ferroptosis (PMID 37696989). That is an animal study in mice with a defined mechanistic target, and its findings apply to that model.

Antioxidant chemistry and dietary framing

Much of the early interest in fisetin came from its antioxidant chemistry. A 2013 review in Antioxidants and Redox Signaling described fisetin as a dietary antioxidant studied for health promotion and surveyed the mechanisms reported across the literature available at that time (PMID 23121441). Antioxidant activity measured in chemical and cellular assays does not establish clinical effect, and the 2024 senotherapeutic review treated fisetin as a research candidate on that basis (PMID 39384074).

Where the evidence is weak or absent

Several questions commonly attached to fisetin are not answered by the sources cited here.

• Human outcome trials: none of the papers cited on this page is a clinical trial of fisetin in a patient population; the human-facing discussion appears in review form only (PMID 39384074).
• Longevity or lifespan claims: the cited senescence work is mechanistic and preclinical, covering senomorphic readouts in cell models (PMID 40806616) and senolytic strategy in dystrophic mouse muscle (PMID 36084954), not lifespan endpoints in humans.
• Cancer treatment: the oncology findings cited are laboratory signalling studies in pancreatic and oral cancer models (PMID 34821587, PMID 32158195), which do not establish clinical efficacy.
• Comparisons with pharmaceuticals: the metformin review cited describes metformin, not fisetin, and no head-to-head comparison appears in the sources here (PMID 31522175).

Adverse Events: What Studies Report

The sources cited on this page are laboratory experiments, animal experiments and reviews, and they report mechanistic and efficacy-style readouts rather than human safety outcomes. The 2013 review characterised fisetin as a dietary antioxidant studied for health promotion (PMID 23121441), and the 2024 senotherapeutic review discussed fisetin as a candidate agent whose clinical position remains under investigation (PMID 39384074). No adverse-event rates in human populations are drawn from the citation set used here, and none are inferred. Safety questions about any compound belong with a licensed physician.

How to read findings like these

1. Check the study type. In vitro findings describe cells or molecules in a dish, as in the alpha-synuclein aggregation work (PMID 34199487).
2. Check the model. Mouse findings describe mice, as in the kidney fibrosis study (PMID 37696989).
3. Check whether a title names the compound. A senolytic strategy paper may not be a fisetin paper (PMID 36084954).
4. Check whether a source is a review. Systematic reviews aggregate prior studies, as in the neuroprotection review (PMID 37453993).

Summary and related reading

Across the cited literature, fisetin has been studied in senescence biology (PMID 39384074, PMID 40806616), neurological disease models (PMID 37453993), cancer cell signalling (PMID 34821587), cardiac cell death pathways (PMID 32076073) and kidney fibrosis in mice (PMID 37696989). Fisetin is not approved by the FDA as a medicine for any condition. This page is not guidance. For background on the molecule itself, see the fisetin learn page.

References

• Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases (Mechanisms of Ageing and Development, 2024)
• Targeting Cellular Senescence with Liposome-Encapsulated Fisetin: Evidence of Senomorphic Effect (International Journal of Molecular Sciences, 2025)
• Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle (Aging, 2022)
• The Neuroprotective Role of Fisetin in Different Neurological Diseases: a Systematic Review (Molecular Neurobiology, 2023)
• Small Molecule Fisetin Modulates Alpha-Synuclein Aggregation (Molecules, 2021)
• Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling (Aging, 2021)
• Fisetin Modulates Human Oral Squamous Cell Carcinoma Proliferation by Blocking PAK4 Signaling Pathways (Drug Design, Development and Therapy, 2020)
• Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential (Biomolecules, 2019)
• Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity (Scientific Reports, 2020)
• Fisetin ameliorates fibrotic kidney disease in mice via inhibiting ACSL4-mediated tubular ferroptosis (Acta Pharmacologica Sinica, 2024)
• Fisetin: a dietary antioxidant for health promotion (Antioxidants and Redox Signaling, 2013)
• Metformin and Aging: A Review (Gerontology, 2019)